Abstract
In trypanosomatids, redox homeostasis is centered on trypanothione (N1,N8-bis(glutathionyl)spermidine, T(SH)2), a low molecular weight thiol that is distinctive for this taxonomic family and not present in the mammalian host. Thus, the study of the metabolism of T(SH)2 is interesting as a potential therapeutic target. In this review, we summarize the existing evidence about the metabolism of thiols in Trypanosoma cruzi, focused on those proteins that can be considered the best candidates for selective therapy. Herein, we examine the biosynthetic pathway of T(SH)2, identifying three key points that are susceptible to attack pharmacologically: the activity of the trypanothione reductase (TR), the function of glutamate-cysteine ligase (GCL) and polyamine transport in T. cruzi. TR has been widely studied and is a good example for the development of the medicinal chemistry of antichagasic compounds. Conversely, GCL and the polyamine uptake system are high flow points in the reductive metabolism of the parasite. However, very little is known at the molecular level about these two systems. Therefore, their potential as targets for drug development is discussed, and it is suggested that research should focus on the production of alternative drugs for Chagas' disease treatment.
Keywords: Chagas’ disease, glutamate-cysteine ligase, glutathione, polyamine uptake, trypanothione, trypanothione reductase, Trypanosoma cruzi.
Current Medicinal Chemistry
Title:Key Proteins in the Polyamine-Trypanothione Pathway as Drug Targets Against Trypanosoma cruzi
Volume: 21 Issue: 15
Author(s): J.D. Maya, C.O. Salas, B. Aguilera-Venegas, M.V. Diaz and R. Lopez-Munoz
Affiliation:
Keywords: Chagas’ disease, glutamate-cysteine ligase, glutathione, polyamine uptake, trypanothione, trypanothione reductase, Trypanosoma cruzi.
Abstract: In trypanosomatids, redox homeostasis is centered on trypanothione (N1,N8-bis(glutathionyl)spermidine, T(SH)2), a low molecular weight thiol that is distinctive for this taxonomic family and not present in the mammalian host. Thus, the study of the metabolism of T(SH)2 is interesting as a potential therapeutic target. In this review, we summarize the existing evidence about the metabolism of thiols in Trypanosoma cruzi, focused on those proteins that can be considered the best candidates for selective therapy. Herein, we examine the biosynthetic pathway of T(SH)2, identifying three key points that are susceptible to attack pharmacologically: the activity of the trypanothione reductase (TR), the function of glutamate-cysteine ligase (GCL) and polyamine transport in T. cruzi. TR has been widely studied and is a good example for the development of the medicinal chemistry of antichagasic compounds. Conversely, GCL and the polyamine uptake system are high flow points in the reductive metabolism of the parasite. However, very little is known at the molecular level about these two systems. Therefore, their potential as targets for drug development is discussed, and it is suggested that research should focus on the production of alternative drugs for Chagas' disease treatment.
Export Options
About this article
Cite this article as:
Maya J.D., Salas C.O., Aguilera-Venegas B., Diaz M.V. and Lopez-Munoz R., Key Proteins in the Polyamine-Trypanothione Pathway as Drug Targets Against Trypanosoma cruzi, Current Medicinal Chemistry 2014; 21 (15) . https://dx.doi.org/10.2174/0929867320666131119122145
DOI https://dx.doi.org/10.2174/0929867320666131119122145 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Adipokines, Metabolism and the Immune Response in the Regulation of Inflammation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Obesity and Inflammation – Targets for OA Therapy
Current Drug Targets Duration of Dual Antiplatelet Therapy After Coronary Stenting
Current Pharmaceutical Design Recent Patents on Biomedical Applications for the Treatment of Atherosclerosis
Recent Patents on Regenerative Medicine The Effect of Antihypertensive Drugs on Central Blood Pressure Beyond Peripheral Blood Pressure. Part I: (Patho)-Physiology, Rationale and Perspective on Pulse Pressure Amplification
Current Pharmaceutical Design The Genetics of Small-Vessel Disease
Current Medicinal Chemistry Treatment of Chronic Peripheral Arterial Disease
Current Vascular Pharmacology Patent Annotations
Recent Patents on Cardiovascular Drug Discovery Pharmacological Interventions on Asymmetric Dimethylarginine, a Clinical Marker of Vascular Disease
Current Medicinal Chemistry Raloxifene and Cardiovascular Health: Its Relationship to Lipid and Glucose Metabolism, Hemostatic and Inflammation Factors and Cardiovascular Function in Postmenopausal Women
Current Pharmaceutical Design Editorial (Thematic Issue: New Therapeutic Targets in Clinical Medicine)
Current Pharmaceutical Design Nanotechnology: A Novel Approach for Drug Development in Health Care System
Current Nanomaterials Oral Antidiabetic Agents: Anti-Atherosclerotic Properties Beyond Glucose Lowering?
Current Pharmaceutical Design Role of GSK-3 in Cardiac Health: Focusing on Cardiac Remodeling and Heart Failure
Current Drug Targets Gene Patents in the Primary Prevention of Vascular Diseases
Recent Patents on DNA & Gene Sequences Cardiovascular Effects of Hypoglycemic Agents in Diabetes Mellitus
Current Drug Safety Adipose Tissue Oxygenation in Obesity: A Matter of Cardiovascular Risk?
Current Pharmaceutical Design Pharmacological and Lifestyle Factors Modulating Serum Paraoxonase-1 Activity
Mini-Reviews in Medicinal Chemistry Strategies to Tackle Early Low Flow States in the Extremely Preterm Infant
Current Pediatric Reviews Circulating Endothelial Progenitor Cells Characterization, Function and Relationship with Cardiovascular Risk Factors
Current Pharmaceutical Design